These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 27656852)

  • 21. Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based study.
    Hendriks LE; Derks JL; Postmus PE; Damhuis RA; Houben RM; Troost EG; Hochstenbag MM; Smit EF; Dingemans AM
    Eur J Cancer; 2015 Nov; 51(17):2534-44. PubMed ID: 26323530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC.
    Kawaguchi T; Takada M; Kubo A; Matsumura A; Fukai S; Tamura A; Saito R; Maruyama Y; Kawahara M; Ignatius Ou SH
    J Thorac Oncol; 2010 May; 5(5):620-30. PubMed ID: 20354456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer.
    Kim YT; Seong YW; Jung YJ; Jeon YK; Park IK; Kang CH; Kim JH
    J Thorac Oncol; 2013 Feb; 8(2):171-8. PubMed ID: 23287850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic indices in stereotactic radiotherapy of brain metastases of non-small cell lung cancer.
    Kaul D; Angelidis A; Budach V; Ghadjar P; Kufeld M; Badakhshi H
    Radiat Oncol; 2015 Nov; 10():244. PubMed ID: 26611493
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Spanish Society of Pulmonology and Thoracic Surgery Lung Cancer Cooperative Group-II registry. A descriptive study.
    Sánchez de Cos Escuín J; Serra Mitjans M; Hernández Hernández J; Hernández Rodríguez H; Abal Arca J; Parente Lamelas I; León Atance P; Núñez Ares A; Miravet Sorribes L; Blanco Orozco AI; Melchor ĺñiguez R; García Arangüena L; Arnau Obrer A; Guijarro Jorge R; Padilla Alarcón J; Peñalver Cuesta JC; Mariñán Gorospe M; Fernández Araujo E; Francisco Corral G; Cerezo González S; González Casaurrán G; Naranjo Gozalo S; Álvarez de Arriba C; Núñez Delgado M; González Budiño MT; Magaroles R; de Esteban Júlvez L; Pavón Fernández MJ; Gullón Blanco JA; de Olaiz Navarro B; Escobar Campuzano I; Macía Vidueira I; García Barajas S; Herrero Collantes J; Freixenet Gilabert J; Saura Vinuesa A
    Arch Bronconeumol; 2013 Nov; 49(11):462-7. PubMed ID: 23838409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Survival status of stage IV non-small cell lung cancer patients after radiotherapy--a report of 287 cases].
    Cai Y; Wang WL; Xu B; Zhu GY; Zhang SW
    Ai Zheng; 2006 Nov; 25(11):1419-22. PubMed ID: 17094913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Lung cancer in Senegal].
    Niang A; Bonnichon A; Ba-Fall K; Dussart C; Camara P; Vaylet F; Mbaye PS; L'Her P; Sane M; Margery J
    Med Trop (Mars); 2007 Dec; 67(6):651-6. PubMed ID: 18300532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer.
    Ren S; Terman DS; Bohach G; Silvers A; Hansen C; Colt H; Sahn SA
    Chest; 2004 Nov; 126(5):1529-39. PubMed ID: 15539723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors.
    Chen KY; Chen JH; Shih JY; Yang CH; Yu CJ; Yang PC
    J Thorac Oncol; 2010 Jan; 5(1):82-9. PubMed ID: 19884854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
    Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
    Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fibroblast growth factor 2--a predictor of outcome for patients irradiated for stage II-III non-small-cell lung cancer.
    Rades D; Setter C; Dahl O; Schild SE; Noack F
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):442-7. PubMed ID: 20950963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy.
    Koch A; Fohlin H; Sörenson S
    J Thorac Oncol; 2009 Mar; 4(3):326-32. PubMed ID: 19155996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Analysis of prognostic factors and efficacy of surgical treatment for non-small cell lung cancer: department of surgery NTLDRI (1998-1999)].
    Chabowski M; Orłowski TM; Rabczenko D
    Pneumonol Alergol Pol; 2008; 76(1):1-10. PubMed ID: 18283649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601).
    Decroisette C; Monnet I; Berard H; Quere G; Le Caer H; Bota S; Audigier-Valette C; Geriniere L; Vernejoux JM; Chouaid C;
    J Thorac Oncol; 2011 Mar; 6(3):576-82. PubMed ID: 21270669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone.
    Yovino S; Kwok Y; Krasna M; Bangalore M; Suntharalingam M
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1438-43. PubMed ID: 16029805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant chemotherapy for non-small cell lung cancer: practice patterns and outcomes in the general population of Ontario, Canada.
    Booth CM; Shepherd FA; Peng Y; Darling G; Li G; Kong W; Mackillop WJ
    J Thorac Oncol; 2012 Mar; 7(3):559-66. PubMed ID: 22307012
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials.
    Di Maio M; Lama N; Morabito A; Smit EF; Georgoulias V; Takeda K; Quoix E; Hatzidaki D; Wachters FM; Gebbia V; Tsai CM; Camps C; Schuette W; Chiodini P; Piccirillo MC; Perrone F; Gallo C; Gridelli C
    Eur J Cancer; 2010 Mar; 46(4):735-43. PubMed ID: 20045311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radiation therapy for brain metastases from lung carcinoma. Prospective randomized trial according to the level of lactate dehydrogenase.
    Chatani M; Matayoshi Y; Masaki N; Inoue T
    Strahlenther Onkol; 1994 Mar; 170(3):155-61. PubMed ID: 8160096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of survivin expression in stage III non-small cell lung cancer patients treated with platinum-based therapy.
    Cho HJ; Kim HR; Park YS; Kim YH; Kim DK; Park SI
    Surg Oncol; 2015 Dec; 24(4):329-34. PubMed ID: 26690822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical characteristics and survival in never smokers with lung cancer.
    Parente Lamelas I; Abal Arca J; Blanco Cid N; Alves Pérez MT; Dacal Quintas R; Gómez Márquez H; García Montenegro RA; Marcos Velázquez P
    Arch Bronconeumol; 2014 Feb; 50(2):62-6. PubMed ID: 24280242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.